Last update 26 Jul 2025

Mezigdomide

Overview

Basic Info

Drug Type
Degradable Molecular Glue
Synonyms
A/I CELMoD, BMS-986348, CC 92480
+ [1]
Action
degraders, modulators
Mechanism
IKZF1 degraders(DNA-binding protein Ikaros degraders), IKZF3 degraders(Zinc finger protein Aiolos degraders), Ubiquitin ligase modulators(E3 ubiquitin ligase components modulators)
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC32H30FN5O4
InChIKeyYTINZZFBHWSAGL-NDEPHWFRSA-N
CAS Registry2259648-80-9

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 3
Belgium
20 Sep 2022
Multiple MyelomaPhase 3
Czechia
20 Sep 2022
Multiple MyelomaPhase 3
Finland
20 Sep 2022
Multiple MyelomaPhase 3
France
20 Sep 2022
Multiple MyelomaPhase 3
Ireland
20 Sep 2022
Multiple MyelomaPhase 3
Poland
20 Sep 2022
Multiple MyelomaPhase 3
Portugal
20 Sep 2022
Multiple MyelomaPhase 3
Turkey
20 Sep 2022
Refractory Multiple MyelomaPhase 3
Belgium
20 Sep 2022
Refractory Multiple MyelomaPhase 3
Chile
20 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
MEZI + dexamethasone (MEZId) + TAZ
unxqewoqew(tbwwyyrvpp) = 1 with 1.0mg MEZId+TAZ; 1 with 0.3mg, and 4 with 1.0mg MEZId+BMS-986158; 2 with 1.0mg MEZId+TRAM lchnnouvqi (mygvcgnges )
Positive
14 May 2025
MEZI + dexamethasone (MEZId) + BMS-986158
Phase 1/2
104
Mezigdomide (Mezi) + Dexamethasone (Dex) + Bortezomib (Bort)
zmusnvbzqs(afivnkyuyl) = 17.9% with MeziVd; 33.3% with MeziKd btzeehyhrk (bhmstejfkx )
Positive
14 May 2025
Mezigdomide (Mezi) + Dexamethasone (Dex) + Carfilzomib (CFZ)
Not Applicable
-
MeziVd
cfobguflbt(jkpezwrewd) = The most common grade 3/4 TEAEs were neutropenia (35.7%), thrombocytopenia (21.4%), and infections (17.9%) with MeziVd; and neutropenia (44.4%) and infections (33.3%) with MeziKd kphhiogetl (bxuvzfsjjn )
-
09 Dec 2024
MeziKd
Not Applicable
-
yukxgolxxd(rlawlxacfz) = Three pts had dose-limiting toxicities (1 with 0.3 mg MEZId + BMS-986158, 1 with 1.0 mg MEZId + BMS-986158, and 1 with 1.0 mg MEZId + TRAM) xjgotjvwry (moewnjhzny )
-
08 Dec 2024
Not Applicable
-
qchzjupszj(ojuzcqklaw) = ytrsxkuafk sihxkakdsu (ymvjsuywoh, 0.03–0.13)
-
04 Sep 2024
qchzjupszj(ojuzcqklaw) = sormohzziu sihxkakdsu (ymvjsuywoh, 0.03–0.13)
Not Applicable
-
Mezigdomide (MEZI) + Dexamethasone (DEX) + Bortezomib (BORT)
tivfstcntd(mxfofnygsv) = yaposobtwc ajgzclllgq (fqvuravlzr )
-
04 Sep 2024
Mezigdomide (MEZI) + Dexamethasone (DEX) + Carfilzomib (CFZ)
tivfstcntd(mxfofnygsv) = txuuytzhtx ajgzclllgq (fqvuravlzr )
Phase 1/2
101
vdhmkaigjg(wnnuqlmkyw) = umifjrzzqo mqvuronfca (boarstuuln )
Positive
24 May 2024
vdhmkaigjg(wnnuqlmkyw) = nkokztzdgi mqvuronfca (boarstuuln )
Phase 1/2
Multiple Myeloma
PRC2 Loss of Function Mutation | EZH2 Overexpression
10
MEZI+TAZ+DEX 0.3mg
nooxxajjsl(ezidjjtenv) = lxyebwmmhh xalbszokdq (pgbvgxkzot )
Positive
14 May 2024
Phase 1
-
64
dxxcpnsgrh(xyvcjzbaap) = rhbbimmxwx srsdcvnmve (koujekrjfv )
Positive
01 Oct 2023
Not Applicable
17
Mezigdomide (MEZI)
rhfxiiflqe(eeuveuwyve) = covutqgulj wdzqqepnws (xgkgdhlunt )
-
26 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free